問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of Hematology & Oncology

Division of General Internal Medicine

Division of Rheumatology

Division of Others-

National Taiwan University Hospital Hsin-Chu Branch (在職)

Division of Hematology & Oncology

National Taiwan University Cancer Center

Division of Hematology & Oncology

更新時間：2023-09-19

姚明YAO, MING
  • Principal Investigator
  • Clinical Trial Experience (year) 23 years 9 個月

Recruiting Trial

159Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

姚明

List

249Cases

2016-09-08 - 2019-10-31

Phase III

A randomized, double-blind phase 3 study of vadastuximab talirine (SGN-CD33A) versus placebo in combination with azacitidine or decitabine in the treatment of older patients with newly diagnosed acute myeloid leukemia (AML)

  • Condition/Disease

    Acute Myeloid Leukemia (AML)

  • Test Drug

    Vadastuximab Talirine

Participate Sites
4Sites

Terminated4Sites

蕭樑材
Taipei Veterans General Hospital

2022-04-01 - 2025-12-31

Phase I/II

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Not yet recruiting1Sites

Recruiting4Sites

2021-03-17 - 2025-06-15

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting8Sites

2021-05-10 - 2022-09-26

Phase II

A Phase 1/2 Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of AMG 701 Monotherapy, or in Combination with Pomalidomide with and without Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (ParadigMM-1B)

  • Condition/Disease

    Relapsed/Refractory Multiple Myeloma

  • Test Drug

    AMG701

Participate Sites
3Sites

Terminated3Sites

2021-05-20 - 2025-12-31

Phase IV

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2019-11-17 - 2021-12-31

Phase III

A Phase III Randomized Placebo-Controlled Study to Examine the Efficacy and Safety of DAS181 for the Treatment of Lower Respiratory Tract Parainfluenza Infection in Immunocompromised Subjects

  • Condition/Disease

    Lower Respiratory Tract Parainfluenza Infection

  • Test Drug

    DAS181

Participate Sites
2Sites

Recruiting2Sites

2023-03-19 - 2026-03-16

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Not yet recruiting3Sites

2021-09-30 - 2030-04-04

Phase III

Phase 3 Randomized, Controlled Study of Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia With Safety Run-in (Golden Gate Study)

  • Condition/Disease

    Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL)

  • Test Drug

    BLINCYTO for Injection

Participate Sites
5Sites

Recruiting5Sites

2021-08-02 - 2026-09-18

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2021-09-02 - 2026-05-25

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

1 19 20 21 22 23 25
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB